Brought to you by:
SYMPHONY-PE trial demonstrates positive efficacy, efficiency, and safety results
Imperative Care has announced efficacy and safety results from the pivotal SYMPHONY-PE trial evaluating the company’s Symphony thrombectomy system in the treatment of acute pulmonary embolism (PE). Results of the SYMPHONY-PE trial were presented in a late-breaking session at the…
Imperative Care announces FDA clearance for Symphony thrombectomy system
Imperative Care has today announced Food and Drug Administration (FDA) 510(k) clearance of its Symphony thrombectomy system to treat pulmonary embolism (PE). This clearance expands the use of Symphony—previously for the treatment of venous thrombosis—to now include PE, providing a…
Akura Medical enrols first patient in QUADRA-PE study
Akura Medical has announced today the first patient enrolment in the QUADRA-PE study evaluating the Katana thrombectomy system in patients with acute pulmonary embolism (PE). The initial procedure was successfully performed by Samuel Horr, director of cardiovascular research at TriStar Centennial…
Penumbra launches Element vascular access system for VTE
Penumbra recently announced the launch of its Element vascular access system. This is the first laser-cut hypotube sheath designed for venous thromboembolism (VTE), the company shares in a press release. Penumbra notes that Element is compatible with the Lightning Flash…
New analysis shows patients treated with Penumbra’s CAVT technology for PE utilize fewer hospital resources
Penumbra has announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra’s computer-assisted vacuum thrombectomy (CAVT) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other…
Thrombolex begins enrolment in RAPID-PE study of Bashir catheter
Thrombolex has announced the enrolment of the first two patients in the RAPID-PE study using the Bashir endovascular catheter for the treatment of acute pulmonary embolism (PE). The patients were enrolled by Ayman Iskander (St Joseph’s Health Hospital, Syracuse, USA).…
Thrombolex and Aidoc announce strategic partnership to advance breakthrough PE treatment
Thrombolex and Aidoc have announced a strategic partnership aimed at revolutionising the treatment of acute pulmonary embolism (PE), a press release reports. This strategic collaboration, the release details, will leverage Aidoc’s artificial intelligence (AI) technology to accelerate patient identification and…
Penumbra announces FDA clearance of Lightning Flash 2 for the treatment of PE
Penumbra has announced the US Food and Drug Administration (FDA) clearance and launch of Lightning Flash 2, the next generation computer assisted vacuum thrombectomy (CAVT) system to remove venous thrombus and treat pulmonary embolism (PE), a press release states. Lightning Flash…
Akura thrombectomy system for PE appears safe and demonstrates reduction of RV/LV ratio in first-in-human study
Results from a first-in-human, prospective, single-arm study of the Akura Medical thrombectomy system (Akura Medical) for pulmonary embolism (PE) were revealed this week at The VEINS 2023 (28–30 October, Las Vegas, USA). Presenter Jay Mathews (Manatee Memorial Hospital, Bradenton, USA)…
FLAME, FLASH and ongoing PEERLESS trials collect ‘compelling’ data for FlowTriever device
Speaking on the FLAME, FLASH and PEERLESS trials that each collected data on the FlowTriever (Inari Medical) device for the treatment of pulmonary embolism (PE), Ripal Gandhi, MD, Miami Cardiac & Vascular Institute & Miami Cancer Institute, Miami, elaborated on…